Pulmokine Inc.

We are developing a novel inhaled kinase inhibitor for PAH to meet an unmet clinical need, with an estimated market share over $500 M USD, and exit at 2 years.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Rensselaer, NY, US
  • Currency USD
  • Founded November 2007
  • Employees 5
  • Incorporation Type C-corp
  • Website pulmokine.net

Company Summary

Pulmokine is developing a novel inhaled PDGF receptor small molecule kinase inhibitor to treat Pulmonary Arterial Hypertension (PAH). PAH is an orphan disease with high mortality. We have raised $6M in non-dilutive funding from the NIH and received $1M from Broadview Ventures An IND for a phase 1 trial was filed in June 2017. Seeking $250-500K. Exit after phase 1.
PAH market: >$4B.

Team

  • Lawrence Zisman
    CEO

    Previous head of cardiovascular drug development, Cytopia. Board certified in cardiovascular medicine with specialization in pulmonary hypertension, heart failure.

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free